Cancer-associated fibroblasts induce trastuzumab resistances in HER2-positive breast cancer

被引：0
|
作者：
Mao, Y. [1 ]
Qu, Q. [2 ]
Zhang, Y. [1 ]
Liu, J. [1 ]
Shen, K. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Comprehens Breast Hlth Ctr, Ruijin Hosp, Shanghai 200030, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Dept Oncol, Ruijin Hosp, Shanghai 200030, Peoples R China
来源：
BREAST | 2015年 / 24卷
关键词：
D O I：
10.1016/S0960-9776(15)70056-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P005
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [1] Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells
    Mao, Yan
    Zhang, Yuzi
    Qu, Qing
    Zhao, Meizhong
    Lou, Ying
    Liu, Junjun
    Huang, Ou
    Chen, Xiaosong
    Wu, Jiayi
    Shen, Kunwei
    [J]. MOLECULAR BIOSYSTEMS, 2015, 11 (04) : 1029 - 1040
  • [2] Effect of cancer-associated fibroblasts on trastuzumab resistance by activating multiple pathways in HER2-positive breast cancer
    Mao, Yan
    Qu, Qing
    Chen, Xiaosong
    Zhang, Yuzi
    Liu, Junjun
    Wang, Gen
    Xiao, Gang
    Wang, Xiumin
    Shen, Kunwei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer
    Luque, Melani
    Sanz-Alvarez, Marta
    Santamaria, Andrea
    Zazo, Sandra
    Cristobal, Ion
    de la Fuente, Lorena
    Minguez, Pablo
    Eroles, Pilar
    Rovira, Ana
    Albanell, Joan
    Madoz-Gurpide, Juan
    Rojo, Federico
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (24)
  • [4] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [5] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    [J]. LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
  • [6] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    [J]. LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [7] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    [J]. LANCET, 2005, 366 (9486): : 634 - 634
  • [8] Trastuzumab (herceptin) and HER2-positive breast cancer
    Murray, S
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (01) : 36 - 37
  • [9] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    [J]. ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
  • [10] HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch
    Dubianski, R.
    Sarnowska, E.
    Leszczynski, M.
    Kubala, S.
    Olszewski, W.
    Rusetska, N.
    Jagiello-Gruszfeld, A. I.
    Konopinski, R.
    Sarnowski, T. J.
    Siedlecki, J. A.
    Nowecki, Z. I.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
12345